{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Zhao T"],"funding":["National Natural Science Foundation","Beijing, Guangzhou Institute of Pediatrics/ Guangzhou Women and Children's Medical Center funds","Guangzhou Municipal Science and Technology Program","Beijing, Guangzhou Institute of Pediatrics/ Guangzhou Women and Children&apos;s Medical Center funds"],"pagination":["2369-2380"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9890293"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["20(12)"],"pubmed_abstract":["<h4>Background</h4>GABAergic deficits have been considered to be associated with the pathophysiology of schizophrenia, and hence, GABA receptors subtype A (GABA<sub>A</sub>Rs) modulators, such as commonly used volatile anesthetic sevoflurane, may have therapeutic values for schizophrenia. The present study investigates the therapeutic effectiveness of low-concentration sevoflurane in MK801-induced schizophrenia-like mice and schizophrenia patients.<h4>Methods</h4>Three weeks after MK801 administration (0.5 mg kg<sup>-1</sup>, i.p. twice a day for 5 days), mice were exposed to 1% sevoflurane 1hr/day for 5 days. Behavioral tests, immunohistochemical analysis, western blot assay, and electrophysiology assessments were performed 1-week post-exposure. Ten schizophrenia patients received 1% sevo"],"journal":["Current neuropharmacology"],"pubmed_title":["Sevoflurane Ameliorates Schizophrenia in a Mouse Model and Patients: A Pre-Clinical and Clinical Feasibility Study."],"pmcid":["PMC9890293"],"funding_grant_id":["81870823","GCP-2019-002","81671116","GCP-2018-001","GCP-2018-001, GCP-2019-002","81671116, 81870823","201803010025"],"pubmed_authors":["Wu L","Zhou Q","Lin C","Qin J","Zhao T","Shi Z","Wang Y","Ma D","Song X","Ling N"],"additional_accession":[]},"is_claimable":false,"name":"Sevoflurane Ameliorates Schizophrenia in a Mouse Model and Patients: A Pre-Clinical and Clinical Feasibility Study.","description":"<h4>Background</h4>GABAergic deficits have been considered to be associated with the pathophysiology of schizophrenia, and hence, GABA receptors subtype A (GABA<sub>A</sub>Rs) modulators, such as commonly used volatile anesthetic sevoflurane, may have therapeutic values for schizophrenia. The present study investigates the therapeutic effectiveness of low-concentration sevoflurane in MK801-induced schizophrenia-like mice and schizophrenia patients.<h4>Methods</h4>Three weeks after MK801 administration (0.5 mg kg<sup>-1</sup>, i.p. twice a day for 5 days), mice were exposed to 1% sevoflurane 1hr/day for 5 days. Behavioral tests, immunohistochemical analysis, western blot assay, and electrophysiology assessments were performed 1-week post-exposure. Ten schizophrenia patients received 1% sevo","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 Nov","modification":"2025-04-26T13:33:50.307Z","creation":"2025-04-06T14:14:53.141Z"},"accession":"S-EPMC9890293","cross_references":{"pubmed":["35272593"],"doi":["10.2174/1570159X20666220310115846"]}}